Physician profile

Christopher Spittler

Annapolis, MD

NPI 1306891478

$2,992.07

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$601.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Allergan, INC. $2,019.38 2019-2022
Abbvie INC. $520.77 2023-2024 Natrelle Saline-Filled Breast Implants
Integra Lifesciences Corporation $166.00 2020-2022
Sientra, INC. $116.07 2020-2022
Revance Therapeutics, INC. $59.03 2024 Daxxify
Mentor Worldwide LLC $46.65 2019-2024 Mentor Memorygel Resterilizable Gel Sizer
Baxter Healthcare $27.25 2021
Galderma Laboratories, L.P. $19.53 2022
Medtronic, INC. $17.39 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher Spittler

$2,992.07

in general payments reported 2019-2025

Years
2019-2024
Top company
Allergan, INC.

https://glasscript.com/doctor/1304282/christopher-spittler

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.